NSE: AJANTPHARM | BSE: 532331

Mid-range Performer

Download real time

2579.50 -14.30 (-0.55%)

25.98% Fall from 52W High

24,022 NSE+BSE Volume

NSE 11 Sep, 2025 1:17 PM (IST)

32,221.1

Market Cap

High in industry

0.7

Beta 1Year

Very Low volatility

Ajanta Pharma Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for AJANTPHARM, BSE:532331 Ajanta Pharma Ltd.

Ajanta Pharma Ltd.

01 Feb 2022

2579.50

-0.55%

Ajanta Pharma (BUY): Strong revenue growth but margins contract

Buy: Ajanta Pharma Ltd.

Target

BOB Capital Markets Ltd.

Q3 revenue up 12% YoY spurred by branded formulations business in India and Africa; US sales down 14% QoQ to US$ 22mn

Number of FII/FPI investors decreased from 385 to 371 in Jun 2025 qtr

Ajanta Pharma Ltd.

31 Oct 2021

2579.50

-0.55%

Ajanta Pharmaceuticals

Buy: Ajanta Pharma Ltd.

Target

ICICI Securities Limited

Promoters pledged 1.51% of shares in last quarter. Total pledge stands at 14.12% of promoter holdings

Ajanta Pharma Ltd.

31 Jul 2021

2579.50

-0.55%

Ajanta Pharma (BUY): Strong earnings growth; reiterate BUY

Buy: Ajanta Pharma Ltd.

Target

BOB Capital Markets Ltd.

Q1 PAT robust at Rs 1.7bn, up 17% YoY. Sales grew 12% YoY while EBITDA declined 2%

Number of FII/FPI investors decreased from 385 to 371 in Jun 2025 qtr

Ajanta Pharma Ltd.

30 Jul 2021

2579.50

-0.55%

DF, US, Africa drive revenue growth

Buy: Ajanta Pharma Ltd.

Target

Motilal Oswal

Ajanta Pharma (AJP) delivered 1QFY22 earnings marginally below our expectation. Robust growth in Domestic Formulation (DF) / Branded Generics (Africa) was offset by moderate growth in US / Branded Generics (Asia) and enhanced opex towards marketing and promotional activities. AJP is on track to outperform in the Branded Generics segment across DF/Asia/Africa and build a product pipeline for the US market. We tweak our estimates for FY22E/FY23E, factoring in a) a better outlook for the Pain Management, Opthal, and Derma therapies in the DF segment,...

Promoters pledged 1.51% of shares in last quarter. Total pledge stands at 14.12% of promoter holdings

Ajanta Pharma Ltd.

30 Jul 2021

2579.50

-0.55%

Ajanta Pharmaceuticals

Buy: Ajanta Pharma Ltd.

Target

ICICI Securities Limited

Domestic formulations constitute 30% of the total consolidated turnover and is segregated into branded formulations & institutional business Asia accounts for ~35% of export formulations, Africa 33% & US 32%. The...

Ajanta Pharma Ltd. has an average target of 3022.00 from 5 brokers.

Ajanta Pharma Ltd.

03 May 2021

2579.50

-0.55%

Ajanta Pharma (BUY): Another good quarter

Buy: Ajanta Pharma Ltd.

Target

BOB Capital Markets Ltd.

Ajanta Pharma (AJP) reported strong Q4FY21 revenue/EBITDA growth of 11%/56% YoY to Rs 7.6bn/Rs 2.6bn, surpassing consensus estimates by 3%/23%.

Promoters pledged 1.51% of shares in last quarter. Total pledge stands at 14.12% of promoter holdings

Ajanta Pharma Ltd.

01 May 2021

2579.50

-0.55%

Ajanta Pharmaceuticals

Buy: Ajanta Pharma Ltd.

ICICI Securities Limited

Q4 revenues grew 11.0% YoY to | 757 crore. Domestic sales grew 23.2% to | 218 crore whereas emerging markets (branded) de-grew 10.5% YoY to | 273 crore amid logistical challenges in Asia and Africa. US sales grew 21% to | 173 crore. Africa tender business grew 86% YoY to | 80 crore. EBITDA margins improved significantly to 34.3% (vs. 22.2% in Q4FY20) amid better gross margins and lower other expenditure. EBITDA grew 71.4% YoY to | 259 crore. PAT grew 21% YoY to | 159 crore. Delta vis--vis EBITDA was...

Promoters pledged 1.51% of shares in last quarter. Total pledge stands at 14.12% of promoter holdings

Ajanta Pharma Ltd.

03 Feb 2021

2579.50

-0.55%

Ajanta Pharmaceuticals

Buy: Ajanta Pharma Ltd.

Target

ICICI Securities Limited

Q3 results were a beat on all fronts on the back of strong growth in branded generic sales in Emerging markets and India along with better gross margin performance. While the management expects subdued domestic growth in FY21 due to Covid-19, it expects high single digit growth for branded business in Asia, Africa (India, Asia, Africa- ~70% of sales) along with ~20% growth for US. On margins front, change in product mix (higher US revenues) notwithstanding, the management expects ~200-250 bps improvement in FY21, going ahead, with improving operating leverage and...

Ajanta Pharma Ltd. is trading below all available SMAs

Ajanta Pharma Ltd.

02 Feb 2021

2579.50

-0.55%

Branded Generics drives earnings

Buy: Ajanta Pharma Ltd.

Target

Motilal Oswal

Ajanta Pharma (AJP) delivered higher than expected earnings, led by superior growth in the Branded Generics segment. This was further supported by a lower tax rate in 3QFY21. While the pace of ANDA filing has moderated in 9MFY21 due to COVID-related disruptions, it would improve with the easing of lockdown restrictions. We have raised our FY21E/FY22/FY23E estimates by 7.4%/7.1%/6.5% to factor in: a) recovery in DF/Asia/Africa, b) robust ANDA pipeline, and c) improved capacity utilization. We continue to value AJP at 23x 12 months...

Ajanta Pharma Ltd. has an average target of 3022.00 from 5 brokers.

Ajanta Pharma Ltd.

02 Feb 2021

2579.50

-0.55%

Ajanta Pharma (BUY): Another good quarter; resilient outlook to drive stock upside

Buy: Ajanta Pharma Ltd.

Target

BOB Capital Markets Ltd.

Ajanta Pharma (AJP) reported yet another excellent quarter with Q3 revenue/ EBITDA growth of 15%/30% YoY to Rs 7.5bn/Rs 2.4bn, surpassing our estimates by 11%/14%.

Ajanta Pharma Ltd. has an average target of 3022.00 from 5 brokers.

Is Ajanta Pharma Ltd. worth buying?

189 Votes:

Buy 77.25%

Sell 15.87%

Hold 6.88%

RESEARCH REPORTS

Buy SEE REPORTS >

pdf

Hold SEE REPORTS >

pdf